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Introduction
The use of  pegylated interferon (PEG-IFN) and ribavirin is 
considered standard therapy for patients with chronic hepatitis 
C (CHC) [1]. Many adverse effects of  IFN appear to be of  au-
toimmune origin; the literature contains few reports of  vitiligo 
induced by IFN-alpha and rare cases associated with PEG-IFN. 
We report a series of  four cases of  vitiligo witch arising in the 
context of  treatment for chronic hepatitis C.
Materials and Methods
A total of  58 patients were recruited in a prospective, monocen-
tric study on dermatological side effects of  treatment with Peg 
IFN and ribavirin in the HVC, for a period of  one year. Among 
these patients, four cases had presented un induced vitiligo out-
side the injection site of  PEG-INF (8,6 % of  the total), with a 
median time to onset of  twelve weeks. 
Case 1: A 46 year-old female known to have diabetes mellitus and 
CHC under PEG-IFN 1,5 ug/kg/week and ribavirin. Examina-
tion revealed hypopigmented patches over the genital and anal 
area (Figures 1, 2). Wood’s lamp examination showed contrast 
enhancement. There was no personal or family history of  viti-
ligo, alopecia areata or thyroid disease. The patient was given beta-
methasone dipropionate 0.05% cream once a day for 3 months 
and the lesions resolved with minimal residual. IFN was withheld 
for 2 months and resumed again for an additional 10 months
Case 2: A 57 year-old male with CHC was treated with PEG-IFN 
and ribavirin and developed new onset vitiligo over the lip and 
genital area (Figures 3, 4) after 6 months of  taking PEG-IFN 
and ribavirin. There was no personal or family history of  viti-
ligo, alopecia or thyroid disease. He received topical Protopic for 
2 months and he responded very well to treatment.
Case 3: A 54 year-old female known to have goiter and CHC, 
developed ill-defined depigmented macules over the finger, after 
1 months of  initiating therapy. No treatment was given and his 
condition has not changed. There was no personal or family his-
tory of  vitiligo.
Case 4: A 47 year-old male with CHC was treated with PEG-IFN 
and ribavirin and developed new onset vitiligo over the trunk af-
ter 4 months of  initiating therapy (Figure 6). He received topical 
corticosteroids for 3 months and he responded well to treatment. 
There was no personal or family history of  vitiligo, alopecia or 
thyroid disease.
Discussion
Hepatitis C virus (HCV) is a major public health problem world-
wide. The use of  PEG-IFN and ribavirin is the standard therapy 
for patients with CHC and both drugs may cause adverse effects 
[1]. 
PEG-IFN is a protein capable of  inducing antiviral activity in 
cells. Pegylation of  IFN has significantly changed pharmacologic 
properties of  IFN: absorption is slowed (time for peak plasma 
concentration is multiplied by 7), clearance is reduced by about 10 
times and the volume of  distribution is less than 4 times. These 
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Vitiligo is an autoimmune disease characterized by depigmented patches and macules. It is associated with many autoimmune diseases, 
the most common of  which is thyroid diseases. The association between Interferon (IFN) therapy and vitiligo is rarely reported in the 
literature, despite its common usage in many diseases particularly hepatitis C viral infection (HCV). We report four cases of  vitiligo that 
appeared after treating HCV with pegylated IFN.
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Figures 1, 2: hypopigmented patches on the genital and anal area
Figures 3, 4: hypopigmented patches over the lip and genital area
Figure 5. depigmented macules over the finger
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properties reduce the number of  injections to once a week [2]. 
PEG-IFN side effects are dose dependent [3]. IFN-induced de
rmatological side effects can be divided into immune related and 
nonimmune related. Immune mediated dermatological side ef-
fects include psoriasis, pemphigus, vitiligo, alopecia and systemic 
lupus erythematosus [4-5-6];
Occurrence of  vitiligo in patients treated with pegylated IFN for 
viral hepatitis is rarely reported in the literature, being the subject 
of  individual case reports. We herein report four cases arising in 
the context of  treatment for chronic hepatitis C.
Vitiligo is an autoimmun disease characterized by depigmented 
patches and macules. It is associated with many autoimmune dis-
eases. The association between IFN therapy and vitiligo is rarely 
reported in the literature, despite its common usage in hepatitis B 
viral infection, HCV, hematological malignancies and melanoma 
[3-4].
Occurrence of  vitiligo in patients with hepatitis under PEG-IFN 
therapy has been reported to occur as early as 1 month. The long-
est time interval between starting treatment and appearance of  
vitiligo is between 18 and 35 months [7]. However, in our series 
the shortest duration was 1 months, while the longest is 6 months. 
It occurs in the fourth to the sixth decade of  life as clearly noticed 
in our series; and affects both genders equally.
The exact mechanism responsible for this autoimmune phenom-
enon is still unknown, but it most likely related to the biological 
features of  IFN. Two hypotheses have been advanced: the pres-
ence of  monoclonal antibodies directed against tyrosinase and 
melanocyte tyrosinase related protein; and activation of  cytotoxic 
T lymphocytes with inhibition of  suppressor T cell function [7-8].
Autoimmun adverse effects of  IFN therapy, which may include 
vitiligo, should be carefully monitored. The decision to discon-
tinue treatment must be discussed with the patient and based on 
the physician’s clinical evaluation. The patient should be advised 
that skin lesions may persist [1].
Conclusion
The very low incidence of  vitiligo attributable to the treatment 
with PEG-IFN suggests that IFN plays a role in unmasking viti-
ligo in susceptible individuals rather than causing it.
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Figure 6. depigmented macules over the trunk
